Subtopic Deep Dive

SHP2 in RAS-MAPK Signaling
Research Guide

What is SHP2 in RAS-MAPK Signaling?

SHP2 (PTPN11) is a protein tyrosine phosphatase that acts as a critical positive regulator and scaffold in RAS-MAPK signaling downstream of receptor tyrosine kinases.

SHP2 facilitates RAS activation by dephosphorylating RAS-GAPs and scaffolding Grb2-SOS complexes upon receptor tyrosine kinase stimulation (Schlessinger, 2000; Hadari et al., 1998). Gain-of-function mutations in PTPN11 drive Noonan syndrome and cancers via hyperactive MAPK signaling (Bentires-Alj et al., 2004; Chan and Feng, 2006). Over 10 key papers since 1998 document its roles, with Schlessinger (2000) cited 3697 times.

Curated Papers

Key Challenges

Why It Matters

SHP2's essential role in RTK-to-RAS-MAPK signaling positions it as a therapeutic target in RTK-driven cancers like AML, where PTPN11 mutations occur in 30-40% of cases (Bentires-Alj et al., 2004; Chan and Feng, 2006). In development, hyperactive SHP2 causes Noonan syndrome RASopathies, informing precision therapies (Aoki et al., 2015). Schlessinger (2000; 2014) established RTK signaling frameworks enabling SHP2 inhibitor development trials.

Key Research Challenges

Allosteric SHP2 Regulation

SHP2's phosphatase and scaffold functions require distinct allosteric sites, complicating selective inhibitor design (Chan and Feng, 2006). Mutations enhance auto-inhibition relief, activating signaling without full catalysis (Bentires-Alj et al., 2004).

RTK Pathway Crosstalk

SHP2 integrates signals from diverse RTKs like FGFR and MET via adapters like FRS2 and Gab1, creating feedback challenges (Hadari et al., 1998; Schaeper et al., 2000). Heinrich et al. (2003) highlight cytokine overlaps complicating MAPK specificity.

Oncogenic Mutation Effects

PTPN11 mutations variably enhance RAS activation across tumor types, requiring genotype-specific models (Bentires-Alj et al., 2004). Chan and Feng (2006) note phosphatase-independent oncogenesis hinders broad inhibitors.

Essential Papers

Cell Signaling by Receptor Tyrosine Kinases

Joseph Schlessinger · 2000 · Cell · 3.7K citations

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

Peter C. Heinrich, Iris Behrmann, Serge Haan et al. · 2003 · Biochemical Journal · 3.2K citations

The IL (interleukin)-6-type cytokines IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-like cytokine are an importa...

The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells

Farhad Seif, Majid Khoshmirsafa, Hossein Aazami et al. · 2017 · Cell Communication and Signaling · 763 citations

Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Mohamed Bentires‐Alj, J. Guillermo Paez, Frank David et al. · 2004 · Cancer Research · 504 citations

Abstract The SH2 domain-containing protein-tyrosine phosphatase PTPN11 (Shp2) is required for normal development and is an essential component of signaling pathways initiated by growth factors, cyt...

40 YEARS OF IGF1: IGF1 receptor signaling pathways

Fumihiko Hakuno, Shin‐Ichiro Takahashi · 2018 · Journal of Molecular Endocrinology · 422 citations

Insulin-like growth factors (IGFs) bind specifically to the IGF1 receptor on the cell surface of targeted tissues. Ligand binding to the α subunit of the receptor leads to a conformational change i...

Recent advances in RASopathies

Yoko Aoki, Tetsuya Niihori, Shinichi Inoue et al. · 2015 · Journal of Human Genetics · 365 citations

PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase

Rebecca J. Chan, Gen‐Sheng Feng · 2006 · Blood · 360 citations

Abstract Elucidation of the molecular mechanisms underlying carcinogenesis has benefited tremendously from the identification and characterization of oncogenes and tumor suppressor genes. One new a...

Reading Guide

Foundational Papers

Start with Schlessinger (2000) for RTK-to-RAS framework (3697 citations), then Hadari et al. (1998) for SHP2-FRS2 binding, and Schaeper et al. (2000) for Gab1 scaffolding essentials.

Recent Advances

Aoki et al. (2015) on RASopathies; Schlessinger (2014) on RTK therapeutic targeting; Hakuno and Takahashi (2018) on IGF1R-SHP2 links.

Core Methods

Co-IP for protein interactions (Schaeper et al., 2000); mutation screens in tumors (Bentires-Alj et al., 2004); signaling assays in PC12 cells (Hadari et al., 1998).

How PapersFlow Helps You Research SHP2 in RAS-MAPK Signaling

Discover & Search

Research Agent uses citationGraph on Schlessinger (2000) to map 3697-cited RTK papers linking to SHP2-RAS works like Hadari et al. (1998), then findSimilarPapers uncovers Gab1-SHP2 adapters (Schaeper et al., 2000). exaSearch queries 'SHP2 PTPN11 RAS-MAPK mutations cancer' retrieves 50+ OpenAlex papers on Noonan/AML links.

Analyze & Verify

Analysis Agent runs readPaperContent on Bentires-Alj et al. (2004) to extract mutation frequencies in tumors, verifies claims via CoVe against Chan and Feng (2006), and uses runPythonAnalysis to plot MAPK activation stats from supplementary data with GRADE scoring for evidence strength in oncogenic contexts.

Synthesize & Write

Synthesis Agent detects gaps in SHP2 inhibitor selectivity across RTKs, flags contradictions between catalytic vs. scaffold roles (Hadari et al., 1998; Schaeper et al., 2000), then Writing Agent applies latexEditText for pathway diagrams, latexSyncCitations for 10-paper bibliography, and latexCompile for publication-ready reviews; exportMermaid generates RAS-MAPK flowcharts.

Use Cases

"Extract signaling data from SHP2-FGF papers and plot RAS activation curves"

Research Agent → searchPapers 'SHP2 FRS2 FGF' → Analysis Agent → readPaperContent (Hadari et al., 1998) → runPythonAnalysis (pandas/matplotlib on dose-response data) → researcher gets CSV plots of Grb2-SOS binding kinetics.

"Write LaTeX review of SHP2 mutations in RASopathies"

Synthesis Agent → gap detection on Aoki et al. (2015) + Bentires-Alj (2004) → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (10 papers) → latexCompile → researcher gets PDF with SHP2-MAPK figure and bibliography.

"Find code/models for SHP2 allosteric simulations"

Research Agent → paperExtractUrls (Chan and Feng, 2006) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for PTPN11 mutation dynamics and Jupyter notebooks.

Automated Workflows

Deep Research workflow scans 50+ SHP2-RTK papers via searchPapers → citationGraph → structured report on mutation prevalence (Bentires-Alj et al., 2004). DeepScan applies 7-step CoVe to verify SHP2 scaffold roles in Schaeper et al. (2000) with GRADE checkpoints. Theorizer generates hypotheses on SHP2-JAK/STAT crosstalk from Heinrich et al. (2003).

Try Doxa for SHP2 in RAS-MAPK Signaling Research

Frequently Asked Questions

What defines SHP2's role in RAS-MAPK signaling?

SHP2 dephosphorylates RAS-GAPs and scaffolds Grb2-SOS to activate RAS upon RTK stimulation (Schlessinger, 2000; Hadari et al., 1998).

What methods study SHP2-RAS interactions?

Co-immunoprecipitation detects SHP2-FRS2/Grb2 binding; mutagenesis assays test catalytic vs. scaffold roles (Hadari et al., 1998; Schaeper et al., 2000).

What are key papers on SHP2?

Schlessinger (2000, 3697 citations) on RTK signaling; Bentires-Alj et al. (2004, 504 citations) on oncogenic mutations; Chan and Feng (2006, 360 citations) on proto-oncogene status.

What open problems exist?

Developing inhibitors targeting scaffold without catalytic functions; resolving RTK-crosstalk feedback in tumors (Chan and Feng, 2006; Aoki et al., 2015).